On stratified analysis by tumor type, XPDLys751Gln polymorphism was not associated with increased risk of non-melanoma skin cancer, but was significantly related with increased risk of cutaneous melanoma (Gln/Gln vs Lys/Lys: OR=1.15, 95%CI=1.02-1.29, p=0.023; dominant model: OR=1.09, 95%CI=1.01-1.18, p=0.036).
To test this hypothesis, a cohort study was conducted to examine the association between XPDLys751Gln polymorphism and risk of a second primary cancer in individuals with NMSC.